Лечение больных псориатическим артритом. Рекомендации Европейской антиревматической лиги

1. <div><p>Kavanaugh A., Antoni C.E., Gladman D. et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65: 1038-43.</p><p>Mease P.J., Goffe B.S., Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.</p><p>Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7.</p><p>Kaltwasser J.P., Nash P., Gladman D. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthr Rheum 2004; 50: 1939-50.</p><p>Mease P.J., Gladman D.D., Ritchlin C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthr Rheum 2005; 52: 3279-89.</p><p>Kavanaugh A., McInnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthr Rheum 2009; 60: 976-86.</p><p>Mease P.J., Gladman D.D., Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebocontrolled study. Arthr Rheum 2006; 54: 1638-45.</p><p>Menter A., Korman N.J., Elmets C.A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4.Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.</p><p>Jones G., Crotty M., Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000; 3: CD000212.</p><p>Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebocontrolled, crossover trial. Lancet 2009; 373: 633-40.</p><p>Peeters A.J., Dijkmans B.A., van der Schroeff J.G. Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study. Br J Rheum 1992; 31: 502-4.</p><p>Menter A., Korman N.J., Elmets C.A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114-35.</p><p>Wright V., Moll J.M. Psoriatic arthritis. Bull Rheum Dis 1971; 21: 627-32.</p><p>Van den Bosch F., Cryssen B.V., Mielants H. Clinical assessment in the spondy loarthropathies, including psoriatic arthritis. Curr Opin Rheumatol 2006; 18: 354-8.</p><p>McGonagle D., Conaghan P.G., Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthr Rheum 1999; 42: 1080-6.</p><p>Antoni C.E., Kavanaugh A., Kirkham B. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthr Rheum 2005; 52: 1227-36.</p><p>Gladman D.D., Mease P.J., Ritchlin C.T. et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthr Rheum 2007; 56: 476-88.</p><p>Gladman D.D., Mease P.J., Cifaldi M.A. et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007; 66: 163-8.</p><p>Furst D.E., Keystone E.C., Fleischmann R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69(Suppl. 1): i2—29.</p><p>Ritchlin C.T., Kavanaugh A., Gladman D.D. et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.</p><p>Kavanaugh A.F., Ritchlin C.T. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheum 2006; 33: 1417-21.</p><p>Fraser A.D., van Kuijk A.W., Westhovens R. et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64: 859-64.</p><p>Gladman D.D., Mease P.J., Healy P. et al. Outcome measures in psoriatic arthritis. J Rheum 2007; 34: 1159-66.</p><p>Kivitz A.J., Espinoza L.R., Sherrer Y.R. et al. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Sem Arthr Rheum 2007; 37: 164-73.</p><p>Sarzi-Puttini P., Santandrea S., Boccassini L. et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheum 2001; 19(1 Suppl. 22): S17-20.</p><p>Borer J.S., Simon L.S. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthr Res Ther 2005; 7(Suppl. 4): S14-22.</p><p>Latimer N., Lord J., Grant R.L. et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009; 339: b2538.</p><p>Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal antiinflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370: 2138-51.</p><p>Gladman D.D., Farewell V.T. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheum 1999; 26: 2409-13.</p><p>Lard L.R., Visser H., Speyer I. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51.</p><p>Scarpa R., Peluso R., Atteno M. et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheum 2008; 27: 823-6.</p><p>Lie E., van der Heijde D., Uhlig T. et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 671-6.</p><p>Black R.L., O'Brien W.M., Vanscott E.J. et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964; 189: 743-7.</p><p>Visser K., van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68: 1094-9.</p><p>Gupta A.K., Grober J.S., Hamilton T.A. et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheum 1995; 22: 894-8.</p><p>Salvarani C., Macchioni P., Olivieri I. et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheum 2001; 28: 2274-82.</p><p>Clark C.M., Kirby B., Morris A.D. et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279-82.</p><p>Helliwell P.S., Taylor W.J. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheum 2008; 35: 472-6.</p><p>Rosenberg P., Urwitz H., Johannesson A. et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-18.</p><p>Heydendael V.M., Spuls P.I., Opmeer B.C. et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65.</p><p>Eder L., Chandran V., Ueng J. et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010; 49: 1367-73.</p><p>Ritchlin C.T., Kavanaugh A., Gladman D.D. et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.</p><p>Fredriksson T., Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.</p><p>Zink A., Thiele K., Huscher D. et al. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheum 2006; 33: 86-90.</p><p>Hoes J.N., Jacobs J.W., Verstappen S.M. et al. A dverse events of low- to mediumdose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009; 68: 1833-8.</p><p>Antoni C.E., Kavanaugh A., Kirkham B. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthr Rheum 2005; 52: 1227-36.</p><p>Griffiths C.E., Strober B.E., van de Kerkhof P. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.</p><p>Ash Z. A systematic literature review of conventional and biologic drug therapies for the treatment of psoriatic arthritis: current evidence informing the EULAR recommendations for the management of Psoriatic Arthritis. Ann Rheum Dis 2012; 71(3): 319—26.</p><p>Heiberg M.S., Koldingsnes W., Mikkelsen K. et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthr Rheum 2008; 59: 234-40.</p><p>Mease P.J., Ory P., Sharp J.T. et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68: 702-9.</p><p>Mease P.J., Kivitz A.J., Burch F.X. et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheum 2006; 33: 712-21.</p><p>Antoni C.E., Kavanaugh A., van der Heijde D. et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheum 2008; 35: 869-76.</p><p>Zochling J., van der Heijde D., Burgos-Vargas R. et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.</p><p>Braun J., Davis J., Dougados M. et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.</p><p>Braun J., Pham T., Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-24.</p><p>Gomez-Reino J.J., Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthr Res Ther 2006; 8: R29.</p><p>Saad A.A., Ashcroft D.M., Watson K.D. et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthr Res Ther 2009; 11: R52.</p><p>Tam L.S., Tomlinson B., Chu T.T. et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology (Oxford) 2008; 47: 718-23.</p><p>Бадокин В.В., Корсакова Ю.Л., Барскова В.Г. и др. Терапия псориатического артрита инфликсимабом. Совр ревматол 2009; 1: 29-35.</p><p>Gossec L., Smolen J.S., Gaujoux-Viala C. et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.</p></div><br />